The Imbalanced Expression of Matrix Metalloproteinases in Nephrogenic Systemic Fibrosis PDF Print E-mail
Monday, 16 August 2010 10:23
Brent C. Kelly, MD, Leslie Scroggins Markle, MD, Jennifer L. Vickers, MD, Matthew S. Petitt, DO, Sharon S. Raimer, MD, and Catherine McNeese, MD

Background:
Nephrogenic systemic fibrosis (NSF) occurs in patients with renal dysfunction and gadolinium exposure. Although little is known about the pathogenesis of this disease, increased expression of transforming growth factor-b has been recently demonstrated. Other fibrosing conditions have been shown to express an imbalance in matrix metalloproteinase (MMP) expression and their corresponding inhibitors. Myofibroblast differentiation, in which cells often express a-smooth muscle actin and achieve the ability to contract, is also a hallmark of fibrosis.

Objective: We theorized that NSF may overexpress tissue inhibitor of metalloproteinase-1 (TIMP-1), while simultaneously showing decreased expression of MMP-1. As a secondary aim, we sought to evaluate the presence of smooth muscle actin in our samples.

Methods: We applied immunohistochemistry to 16 skin biopsies from 10 patients with NSF using antibodies to TIMP-1, MMP-1, MMP-2, MMP-9, and a-smooth muscle actin. Samples from normal skin, scar, keloid and scleroderma were stained for comparison.

Results: TIMP-1 was strongly expressed in all NSF specimens compared to normal skin. MMP-1 expression was nearly absent in all tested samples. In all 16 NSF cases, the dermal spindle cells did not stain for a-smooth muscle actin. MMP-2 and MMP-9 expression was variable but was increased compared to normal skin.

Limitations: The expression is semiquantitative and based on immunohistochemistry and unconfirmed by other techniques.

Conclusions: In NSF, TIMP-1 is strongly expressed and MMP-1 is nearly absent, characteristic of the MMP imbalances seen in other fibrosing processes. Using smooth muscle actin immunohistochemistry, there was no evidence of myofibroblast differentiation. ( J Am Acad Dermatol 2010;63:483-9.)

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» Multidisciplinary Therapy May Improve Systemic Sclerosis

For patients with (SSc), a multidisciplinary program offers better improvement of grip strength, maximal mouth opening (MMO), six-minute walk distance (6MWD), and SSc Health Assessment Questionnaire (HAQ) score than regular outpatient care,...

» An Approach to the Treatment of Scleroderma

Systemic sclerosis is unique among the rheumatic diseases because it presents the challenge of managing a chronic multisystem autoimmune disease with a widespread obliterative vasculopathy of small arteries that is associated with varying degrees of...

» New Classification Criteria Developed For Scleroderma

The 2013 Classification Criteria for Systemic Sclerosis have been developed and validated by the and and should allow patients to be identified and treated earlier, according to the professional bodies.Published in Arthritis and Rheumatism, the...

» Prevalence and Correlates of Sleep Disturbance in Systemic Sclerosis

Tracy Frech, Ron D. Hays, Paul Maranian, Philip J. Clements, Daniel E. Furst and Dinesh KhannaObjective:Rheumatologic disorders are associated with sleep disturbances. This study examines sleep disturbance correlates in patients with...

» Scleroderma in Children: Emerging Management Issues

Saumya PandaDepartment of Dermatology, KPC Medical College, Kolkata, IndiaDate of Web Publication: 21-Jul-2010Abstract         Scleroderma is a set of rare connective tissue diseases of unknown etiology. It is...

» Genetics of Scleroderma: Implications For Personalized Medicine

Significant advances have been made in understanding the genetic basis of systemic sclerosis (scleroderma) in recent years. Can these discoveries lead to individualized monitoring and treatment? Besides robustly replicated genetic susceptibility...